Mergers and acquisitions are expected to increase under a Republican president, especially as President-elect Donald Trump is ...

Velocity One, a newly formed aerospace manufacturing holding company, announced the acquisition of Emcore Corp. for $31.4 ...

Prior to Rectify, she was Chief Financial Officer at Akouos, Inc., where she led corporate finance ... compared to amounts ...

Alkermes plc announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on PepGen Inc. (PEPG – Research Report) on November 8 and set a price target ...

Stifel Nicolaus upgraded shares of Alkermes (NASDAQ:ALKS – Free Report) from a hold rating to a buy rating in a research note released on Tuesday, Marketbeat Ratings reports. The firm currently has ...

Stifel has upgraded Alkermes (ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug candidate ALKS2680. Read more here.

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs ...

The consensus rating for Ultragenyx Pharmaceutical is Outperform, based on 6 analyst ratings. With an average one-year price target of $102.33, there's a potential 100.69% upside.

Myrobalan Therapeutics, a biotechnology company developing novel oral small-molecule therapies to repair damage and restore brain function in high-unm ...

James Investment Research Inc. purchased a new stake in Alkermes ... Hedge funds and other institutional investors own 95.21% of the company’s stock. Alkermes plc, a biopharmaceutical company ...